Detection of Circulating Tumor cells by ISET and their molecular characterization for use as liquid biopsy

Диагностика циркулирующих опухолевых клеток с помощью технологии ISET и их молекулярная характеристика для жидкостной биопсии
Gulziya Ismailova 1, Sophie Laget 2, Patrizia Paterlini-Bréchot 3
More Detail
1 JSC “National Scientific Medical Research Center”, Astana, Kazakhstan
2 INSERM/Rarecells Diagnostics team, Paris, France
3 University Paris Descartes, INSERM, Paris, France
J CLIN MED KAZ, Volume 1, Issue 35, pp. 15-20.
OPEN ACCESS 4436 Views 3517 Downloads
Download Full Text (PDF)

ABSTRACT

Currently, the detection of theranostic biomarkers is performed on samples of tumor tissue, after pathological analysis. Circulating Tumor Cells (CTC) are a non-invasive source of tumor material potentially highly relevant to guide therapeutic choices and for early detection of resistance to therapy. The ISET (Isolation by Size of Tumor / Trophoblastic cells) method allows cytopathological diagnosis of CTC and their molecular analysis for theranostic analysis aimed to guide the use of targeted therapies. In particular, ISET allows the isolation of CTC without loss and without bias of selection and their immune-molecular characterization, including detection of vimentin, indicating indication their increased metastatic potential, and extensive analysis of gene mutations, such as EGFR, KRAS, ALK, HER2 genes, predictive of response to therapy.
Keywords: circulating tumor cells, ISET, cytopathology, oncogenetics

CITATION

Ismailova G, Laget S, Paterlini-Bréchot P. Detection of Circulating Tumor cells by ISET and their molecular characterization for use as liquid biopsy. Journal of Clinical Medicine of Kazakhstan. 2015;1(35):15-20.

REFERENCES

  • Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions, Cancer Lett, 2007, No.18;253(2), pp.180-204.
  • Wittekind C, Neid M. Cancer invasion and metastasis, Oncology, 2005, No. 69 Suppl 1, pp.14-16.
  • Gupta PB, Mani S, Yang J, Hartwell K, Weinberg RA. The evolving portrait of cancer metastasis, Cold Spring Harb Symp Quant Biol, 2005, No.70, pp.291-297.
  • Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation, Cell, 2012, No.20;148(1-2), pp.349-361.
  • Paterlini Bréchot P. Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis-capable malignancy, Future Oncology, 2011, No.7(5), pp. 849-871.
  • Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, et al. Considerations in the development of circulating tumor cell technology for clinical use, J Transl Med, 2012, No.10, p.138.
  • Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches, J Thorac Oncol, 2012, No.7(2), pp.306-315.
  • Ma YC, Wang L, Yu FL. Recent Advances and Prospects in the Isolation by Size of Epithelial Tumor Cells (ISET) Methodology, Technol Cancer Res Treat, 2012, No. 12(4), pp.295-309.
  • Hofman V, Ilie MI, Long E, Selva E, Bonnetaud C, Molina T, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small cell lung carcinoma: Comparison of the efficacy of the CellSearch Assay and the isolation by size of epithelial tumor cell method, Int J Cancer, 2010, No.2, p.2011.
  • Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas, Br J Cancer, 2011, No. 105(6), pp.847-853.
  • Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker, Br J Cancer, 2012, No.31;106 (3), pp.508-516.
  • Pailler, Emma, Adam J, Barthelemy A, Oulhen M et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non–small-cell lung cancer, Journal of Clinical Oncology, 2013, No.31.18, pp.2273-2281.
  • Mouawia H, Saker A, Jais JP, Benachi A, Bussieres L, Lacour B, et al. Circulating trophoblastic cells provide genetic diagnosis in 63 fetuses at risk for cystic fibrosis or spinal muscular atrophy, Reprod Biomed Online, 2012, No.25(5), pp.508-520.
  • Vona G, Béroud C, Benachi A, Quenette JP, Bonnefont Y, Dumez Y, Lacour B, Paterlini-Bréchot, P. Enrichment and genetic analyses of fetal cells circulating in the maternal blood by the ISET technique and single cell microdissection : a non-invasive tool for early prenatal diagnosis, Am J Pathol, 2002, No.160, pp.51-58.
  • Béroud C, Karliova M, Bonnefont JP, Benachi A, Munnich A, Dumez Y, Lacour B, Paterlini-Bréchot P. Prenatal diagnosis of Spinal Muscular Atrophy (SMA) by genetic analysis of circulating fetal cells, The Lancet, 2003, No.361, pp.1013-1014.
  • Saker A, Benachi A, Bonnefont JP, Munnich A, Dumez Y, Lacour B, Paterlini-Brechot P. Genetic characterization of circulating fetal cells allows non invasive prenatal diagnosis of cystic fibrosis, Prenat Diagn, 2006, No.26, pp.906-916.
  • Lelievre L, Paterlini-Brechot P, Cammatte S, Tartour E, Aggerbeck M, Vilde F, Lecuru F. Effect of laparoscopy versus laparotomy on circulating tumor cells using isolation by size of epithelial tumor cells, Int J Gynecol Cancer, 2004, No.14, pp.229-233.
  • Hofman VJ, Ilie MI, Bonnetaud C, Selva E, Long E, Molina T, et al. Cytopathologic detection of circulating tumor cells using the isolation by size of epithelial tumor cell method: promises and pitfalls, Am J Clin Pathol, 2011, No.135(1), pp.146-156.
  • Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer, J Clin Oncol. 2012, No.30(5), pp.525-532.
  • Chinen L, De Carvalho F, Rocha B, Aguiar C, Abdallah E, Campanha D, Mingues N, De Oliveira T, Maciel M, Cervantes G, Dettino A, Soares F, Paterlini-Brechot P, Fanelli M. Cytokeratin-based CTC counting unrelated to clinical follow up, Journal of thoracic disease, 2013, No.5.5, pp.593.
  • Bidard FC, Hajage D, Bachelot T, Delaloge S, Brain E, et al. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study, Breast Cancer Res, 2012, No.14.1, pp.29.
  • Khoja, L., Shenjere, P., Hodgson, C., Hodgetts, J., et al. Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma, Melanoma research, 2014, No.24(1), pp.40-46.
  • Ilie M, Long E, Butori C, Hofman V, Coelle C, Mauro V, et al. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma, Ann Oncol. 2012, No.23(11), pp.2907-2913.
  • Malapelle U, de Rosa N, Rocco D, Bellevicine C, Crispino C, Illiano A, et al. EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study, J Clin Pathol, 2011, No.65(1), pp.87-91.
  • Vona G, Estepa L, Beroud C, Damotte D, Capron F, Nalpas B, et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer, Hepatology, 2004, No.39(3), pp.792-797.
  • Pinzani P, Salvadori B, Simi L, Bianchi S, Distante V, Cataliotti L, et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection, Hum Pathol. 2006, No.37(6), pp.711-718.
  • Hofman V, Ilie M, Long-Mira E, Giacchero D, Butori C, Dadone B, et al. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients, J Invest Dermatol, 2012, No.133(5), pp.1378-1381.
  • Bidard FC, Pierga JY, Soria JC, Thiery JP. Translating metastasis-related biomarkers to the clinic--progress and pitfalls, Nat Rev Clin Oncol. 2013 , No.10(3), pp.169-179.